Differential Sensitivity of Human Hepatocellular Carcinoma Xenografts to an IGF-II Neutralizing Antibody May Involve Activated STAT3
Sameer A Greenall, Jacqueline Donoghue, Terrance G Johns, Timothy E Adams
TRANSLATIONAL ONCOLOGY | ELSEVIER SCIENCE INC | Published : 2018
Hepatocellular carcinoma (HCC) is highly refractory to current therapeutics used in the clinic. DX-2647, a recombinant human antibody, potently neutralizes the action of insulin-like growth factor-II (IGF-II), a ligand for three cell-surface receptors (IGF-IR, insulin receptor A and B isoforms, and the cation-independent mannose-6-phosphate receptor) which is overexpressed in primary human HCC. DX-2647 impaired the growth of tumor xenografts of the HCC cell line, Hep3B; however, xenografts of the HCC cell line, HepG2, were largely unresponsive to DX-2647 treatment. Analysis of a number of aspects of the IGF signaling axis in both cell lines did not reveal any significant differences between ..View full abstract
Awarded by National Health and Medical Research Council of Australia
T. G. J. (GNT1117501) is supported by a fellowship from the National Health and Medical Research Council of Australia. We acknowledge assistance through the Victorian Government's Operational and Infrastructure Support Program.